Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials

From Bortezomib to other Inhibitors of the Proteasome and Beyond

(2013) Daniela Buac et al.   CURRENT PHARMACEUTICAL DESIGN

Proteasome inhibitors in multiple myeloma: 10 years later

(2012) P. Moreau et al.   BLOOD

First Experience With Proteasome Inhibitor Treatment of Radioiodine Nonavid Thyroid Cancer Using Bortezomib

(2012) Daniel Putzer et al.   CLINICAL NUCLEAR MEDICINE

An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens

(2012) Gabriella Parma et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma

(2012) Dean A. Fennell et al.   Journal of Thoracic Oncology

An Historic Perspective of Proteasome Inhibition

(2012) Dixie-Lee Esseltine et al.   SEMINARS IN HEMATOLOGY

Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial

(2011) Primo N. Lara et al.   Clinical Lung Cancer

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance

(2011) Amy M. Ruschak et al.   JNCI-Journal of the National Cancer Institute

Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003)

(2011) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer

(2011) Benjamin Besse et al.   LUNG CANCER

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

(2011) B. B. Friday et al.   NEURO-ONCOLOGY

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

(2010) D. Chauhan et al.   BLOOD

A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma

(2010) Gary A. Croghan et al.   CANCER

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer

(2010) William J. Irvin et al.   Clinical Breast Cancer

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

(2010) Lawrence R. Dick et al.   DRUG DISCOVERY TODAY

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma

(2010) George P. Kim et al.   INVESTIGATIONAL NEW DRUGS

A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

(2010) Manish A. Shah et al.   INVESTIGATIONAL NEW DRUGS

Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)

(2010) Aminah Jatoi et al.   Journal of Thoracic Oncology

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

(2010) Angela M. Davies et al.   Journal of Thoracic Oncology

A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer

(2010) Thomas J. Lynch et al.   Journal of Thoracic Oncology

Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets

(2010) Lynn Bedford et al.   NATURE REVIEWS DRUG DISCOVERY

Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

(2009) C. H. Chung et al.   ANNALS OF ONCOLOGY

Clinical development of novel proteasome inhibitors for cancer treatment

(2009) Huanjie Yang et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402

(2009) Rogerio Lilenbaum et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)

(2009) Tianhong Li et al.   LUNG CANCER

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer

(2009) Giorgio V. Scagliotti et al.   LUNG CANCER

Targeting the ubiquitin system in cancer therapy

(2009) Daniela Hoeller et al.   NATURE

Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction

(2009) S Baritaki et al.   ONCOGENE

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

(2008) J. E. Rosenberg et al.   ANNALS OF ONCOLOGY

Bortezomib-Mediated Inhibition of Steroid Receptor Coactivator-3 Degradation Leads to Activated Akt

(2008) G. Ayala et al.   CLINICAL CANCER RESEARCH

Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells

(2008) C. M. Sloss et al.   CLINICAL CANCER RESEARCH

Advances in and applications of proteasome inhibitors

(2008) Bradley S Moore et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study

(2008) Peter S. Kozuch et al.   JOURNAL OF CLINICAL ONCOLOGY